Skip to main content

Table 4 Clinical characteristics and results of immunohistochemistry for ASCL1, DKK1 and TPH1

From: Identification of Achaete-scute complex-like 1 (ASCL1) target genes and evaluation of DKK1 and TPH1 expression in pancreatic endocrine tumours

Tumour no Gender Age at
diagnosis
WHO Syndrome ASCL1 DKK1 TPH1
1 M 53 2 NF High Low Heterogeneous
2 F 47 1 NF/MEN 1 High Low Low
3 M 50 2 IN High Low  
4 F 86 1 IN High Low  
5 F 40 1 GA High (p) Low (p) Heterogeneous
6 M 44 2 GL High Low Heterogeneous
7 M 51 2 NF Low High  
8 F 46 2 NF Low High  
9 F 34 2 NF Low High  
10 M 62 1 NF/MEN 1 Low High (p) Heterogeneous (p)
11 M 53 2 NF/MEN 1 Low High  
12 M 48 2 NF/MEN 1 Low N/D Heterogeneous
13 M 47 2 IN Low High Heterogeneous
14 M 19 1 IN/MEN 1 Low High Heterogeneous
15* M 53 2 GL Low High High
16 M 72 2 GA Low High  
17 M 50 3 NF High High  
18 F 44 2 NF High High  
19 F 23 3 NF High High  
20 M 57 1 NF/MEN 1 High High High
21 F 44 1 NF Low Low Heterogeneous
22 M 22 1 NF/MEN 1 Low Low High/Heterogeneous
23 M 64 1 IN Low (p) Low  
  1. Immunoreactivity was graded as Low, High or Heterogeneous. ASCL1 immunoreactivity has been determined previously (8) were grading +, ++ is here denoted Low and +++ denoted High. N/D, not determined; *, liver metastasis; p, in Figure 6. WHO classifications: 1, well-differentiated endocrine tumour, 2, well-differentiated endocrine carcinoma, 3, poorly differentiated endocrine carcinoma. NF, non-functioning; MEN 1, Multiple Endocrine Neoplasia 1; IN, insulinoma; GA, gastrinoma; GL, glucagonoma